Posted on March 26, 2009 by Sitemaster
This morning’s news report addresses items on:
- p53 overexpression and prostate cancer outcomes
- Diet and prostate cancer in newly diagnosed patients and prostate cancer survivors
- Outcomes of surgical treatment of men with clinical T1a and T1b disease
- Peripheral androgen ablation in men with biochemical recurrence after first-line treatment … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment, Uncategorized | Tagged: diet, finasteride, flutamide, p53 overexpression, peripheral androgen blockade, T1a, T1b | Leave a comment »
Posted on July 24, 2008 by Sitemaster
Newly published studies today include data on:
- Risk for patients with prostate atypia on biopsy having a subsequent diagnosis of prostate cancer
- Patterns of failure of patients treated with brachytherapy for localized disease
- Quality of life following differing types of radiotherapy
- Second-line antiandrogen therapy following initial failure of a first-line antiandrogen in advanced prostate cancer
- Mood and cognitive changes in men receiving intermittent androgen deprivation therapy … MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, antiandrogen, atypia, bicalutamide, brachytherapy, cancer, depression, fatigue, flutamide, irritability, mood, prostate, quality of life, radiotherapy | Leave a comment »
Posted on July 22, 2008 by Arnon Krongrad, MD
A paper published today in the Journal of Clinical Oncology suggests that a new agent has been identified for the treatment of end-stage prostate cancer. The paper is being quoted in the media and is likely to reinvigorate discussion about the merits and risks of agents targeting hormone synthetic pathways. Continue reading →
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, cancer, deprivation, flutamide, hormone, prostate, PSA | 10 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 